SunTrust Banks now has a "Buy" rating and a $33.00 target price on the stock. …
The sell-off Wednesday on Bristol-Myers Squibb (BMY) was overdone, analysts said after Bristol failed to meet a key benchmark in a kidney cancer trial — prompting …
Equity analyst Piper Jaffray lowered the price target and downgraded the stock on September 2 cutting the price target from $11.00 to $2.50 and setting the rating at "Neutral" which had previously been "Overweight". Shares of Exelixis …
"Mad Money" host Jim Cramer explains why the stock market is ignoring …
The stock was sold at an average price of $18.46, for a total transaction of $92,300.00. A number of hedge funds have recently made changes to their positions in the company. Exelixis, Inc. (EXEL) has 287.01 Million shares outstanding …
it can quickly be aggregated and run through a spreadsheet to identify potential buy and sell candidates. The inevitable result was a proliferation of algorithmic trading …
Exelixis (NASDAQ: EXEL) also has a solid cancer lineup with Cabometyx ... 10 stocks we like better than Gilead Sciences When investing geniuses David and …
Exelixis, Inc. (EXEL) will report its next earnings on Aug 02 AMC ... Inc. and for the current quarter 9 analysts have projected that the stock could give an Average …
Among them, Exelixis, Inc. (NASDAQ:EXEL) should be at the top of the list. After a 14% fall Wednesday, EXEL stock took another beating Thursday, losing as much as 12% before closing the session down only 8%. Still, if you’re …